Under-reporting in UK prompts MHRA to issue alert
This article was originally published in SRA
Faced with a further reduction in the number of medical device-related adverse incidents being reported by healthcare professionals in the UK, the Medicines and Healthcare products Regulatory Agency has warned senior National Health Service managers that under-reporting can lead to serious safety issues not being identified and prevent the agency pursuing corrective action with manufacturers.
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib
Priority review is likely in the US for Kite’s second CAR-T therapy offering but it seems the company will have to make do with standard review in the EU.